A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
1. To evaluate whether treatment with peginterferon and ribavirin for 24 weeks is
sufficient to achieve a sustained virological response (SVR) rate comparable to that
observed with the standard treatment duration of 48 weeks, in hepatitis C virus genotype
1 (HCV-1) patients achieving a rapid virologic response (RVR; <50 IU/mL HCV RNA at week
4) at 4 weeks.
2. To investigate the role of on-treatment virological responses among patients with 24 or
48 weeks treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital